Neurizon Therapeutics Limited · ASX:NUZ
Neurizon Therapeutics — PharmAust — Shareholder Meeting (November 2018)
10 slides from Neurizon Therapeutics's shareholder meeting presentation, November 2018
Slide 1: PharmAust Ltd AGM 2018: Repurposing MPL for Cancer
PHARMAUST LTD AGM 2018 For personal use only REPURPOSING MPL FOR CANCER
Slide 2: What is MPL (Monepantel)?
What is MPL (Monepantel)? For personal use only Monepantel is a small molecule that: • is readily distributed throughout the body • has proven activity as a livestock healthcare product – to kill parasites invading the gut • has been approved for such veterinary use in Australia, New Zealand, 27 Eur
Slide 3: What is MPL (Monepantel)?
What is MPL (Monepantel)? For personal use only Monepantel is a small molecule that: • has demonstrated good anticancer against many different cancer types in the laboratory setting • has demonstrated early anticancer activity in pet dogs with cancer • has demonstrated preliminary evidence of antica
Slide 4: Companion Market is Changing Fast - Pets are Part of the Family
Companion Market is Changing Fast- Pets are Part of the Family For personal use only The Past The Present Owners and Insurance Policies Cover Pet costs running in 1000s dollars
Slide 5: Development Strategy
Development Strategy For personal use only 1. Demonstrate Value in Canines with global partner 2. Validate and commercialise in man 1. Advantages of Dog Models in Cancer Domesticated dogs (Canis lupus familiaris) are excellent models of human complex diseases for several reasons: • Dogs generally de
Slide 6: Phase II Canine Lymphoma Trial
PHASE II CANINE LYMPHOMA TRIAL For personal use only
Slide 7: Phase II Canine Lymphoma Trial
PHASE II CANINE LYMPHOMA TRIAL For personal use only Seven dogs with B-Cell lymphoma • Open-label 14-day treatment, then proceed to conventional chemotherapy • Different sized dogs: small and large • Different dog breeds • Six of seven dogs had smaller tumours and stable disease • No remarkable adve
Slide 8: Phase I Human Trial
PHASE I HUMAN TRIAL For personal use only Four patients with different cancers • Failed conventional treatments • Open-label 28-day treatment • Three patients 28 days; one patient 14 days • Three patients with stable tumour size • All patients with reduced monepantel anticancer activity markers • Sa
Slide 9: Strong Foundations in Safety and Efficacy of MPL Anticancer
STRONG FOUNDATIONS IN SAFETY AND EFFICACY OF MPL For personal use only ANTICANCER PROTOTYPE TABLET OPTION TABLET PROTOTYPE AGREEMENT MANUFACTURED PERFORMANCE DRUG, VALIDATED SUPPLY OF VALIDATED IN CLINICAL GRADE CANINES WITH MONEPANTEL LYMPHOMA AND ANALOGUES (PHASE II) ACHIEVED DRUG, CANCER ✔ ✔ ✔ NE
Slide 10: MPL Commercialisation
MPL COMMERCIALISATION For personal use only Q1/3 2018 NEW DRUG FORMAT (TABLET) DEVELOPED Q3-Q4 2018 APPROVAL IN CANINES FOR LARGER TRIALS PHASE II IN CANINES - THE PIVOTAL TRIAL FOR MOVING Q2 2019 FORWARD: CANCER CONTROL EXPAND INDICATIONS AND TREATMENT DURATION IN CANINE SECOND HALF 2019 CANCER – D